Next 10 |
2024-04-17 18:51:53 ET For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical ...
2024-04-17 10:30:28 ET More on Inspire Medical Systems Inspire Medical Systems: A Potential Example Of Market Mispricing Inspire Medical Systems: Strong Q4 Results But Growth Might Be Slowing Inspire Medical: A Good Night Sleep Baird puts Inspire on top idea ...
2024-04-17 08:21:19 ET Losers: Arrowroot Acquisition Corp ( AILE ) -34% . Hub Cyber Security Ltd ( HUBC ) -22% . Longeveron ( LGVN ) -18% announces exercise of warrants for $6.2 Million gross proceeds . Sage Therapeutics SAGE -19% after mi...
2024-04-17 07:04:07 ET More on Eli Lilly Eli Lilly: Three Threats To Its Huge Rally Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets GLP-1s ...
2024-04-14 17:56:08 ET More on Boston Scientific, CONMED, etc. ResMed: Not A Sleeper Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash Boston Scientific: The Market's Newest Mega-Cap Needs A Breather Mizuho sees ResMed as 'overwhelming ben...
2024-04-13 05:03:12 ET Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major com...
2024-04-12 13:17:44 ET Short percentage in S&P 500’s healthcare companies surged in the end of March from February, as the life science tools and services sub-sector saw a jump in short interest from the previous month.... Read the full article on Seeking Alpha For fu...
2024-04-10 15:46:35 ET More on ResMed ResMed: Not A Sleeper ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript ResMed Inc. 2024 Q2 - Results - Earnings Call Presentation ResMed positive as Philips halts sales of sleep therapy devices ResMed jumps 9% a...
2024-04-10 08:00:07 ET Craig Wong-Pan from RBC Capital issued a price target of $187.00 for RMD on 2024-04-10 07:09:00. The adjusted price target was set to $187.00. At the time of the announcement, RMD was trading at $194.27. The overall price target consensus is at $21...
2024-04-07 10:21:56 ET Summary ResMed's shares have seen setbacks but still trade at a healthy premium compared to the market, less of a premium compared to the past. The company targets large and growing addressable markets, including sleep apnea, COPD, asthma, and insomnia. ...
News, Short Squeeze, Breakout and More Instantly...
2024-04-17 18:51:53 ET For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical ...
2024-04-10 08:00:07 ET Craig Wong-Pan from RBC Capital issued a price target of $187.00 for RMD on 2024-04-10 07:09:00. The adjusted price target was set to $187.00. At the time of the announcement, RMD was trading at $194.27. The overall price target consensus is at $21...
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. (NYSE: UBER). "I think Uber is ...